Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Medtronic, Inc. (MDT) PT Raised to $155 at Jefferies
August 25, 2021 7:30 AM EDTJefferies analyst Raj Denhoy raised the price target on Medtronic, Inc. (NYSE: MDT) to $155.00 (from $145.00) while maintaining a Buy rating.
The analyst commented, "MDT posted a ~$120mn/$0.10 beat on out-performance in MedSurg on elective procedure recovery, share gains in Cardio/Micra,... More
Medtronic, Inc. (MDT) PT Raised to $145 at Stifel
August 25, 2021 6:33 AM EDTStifel analyst Rick Wise raised the price target on Medtronic, Inc. (NYSE: MDT) to $145.00 (from $140.00) while maintaining a Buy rating.
The analyst commented, "Despite some signs of new COVID-related slowdowns in late-July, Medtronic did start the F2022 year with a better-than-expected overall performance. Nicely-exceeding Stifel/Consensus estimates (Sales: $7.866B/$7.871B; EPS: $1.32), Medtronic reported F1Q sales... More
